CRELD2 and invasive breast carcinoma: Clinically relevant data have also been collected for the Rho kinase ROCK (Boyle et al, 2020) in a study that unraveled a new axis ROCK‐PERK‐ATF4‐CRELD2 active in invasive breast carcinoma.